BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35757402)

  • 1. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
    Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
    Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
    Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
    Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
    Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
    Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
    J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
    Brastianos PK; Twohy E; Geyer S; Gerstner ER; Kaufmann TJ; Tabrizi S; Kabat B; Thierauf J; Ruff MW; Bota DA; Reardon DA; Cohen AL; De La Fuente MI; Lesser GJ; Campian J; Agarwalla PK; Kumthekar P; Mann B; Vora S; Knopp M; Iafrate AJ; Curry WT; Cahill DP; Shih HA; Brown PD; Santagata S; Barker FG; Galanis E
    N Engl J Med; 2023 Jul; 389(2):118-126. PubMed ID: 37437144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
    Gritsch D; Santagata S; Brastianos PK
    Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Medical Therapy of Craniopharyngiomas: The Way Ahead.
    Alexandraki KI; Kaltsas GA; Karavitaki N; Grossman AB
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5751-5764. PubMed ID: 31369091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising response to vemurafenib and cobimetinib treatment for BRAF V600E mutated craniopharyngioma: a case report and literature review.
    Yu N; Raslan OA; Lee HS; Theeler BJ; Raafat TA; Fragoso R; Shahlaie K; Aboud O
    CNS Oncol; 2024 Jan; 13(1):CNS106. PubMed ID: 38348829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
    Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
    Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF plus MEK inhibition effective in papillary craniopharyngioma.
    Sidaway P
    Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37491596
    [No Abstract]   [Full Text] [Related]  

  • 12. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
    Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
    World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
    Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
    Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
    Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
    Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted Therapy in the Management of Modern Craniopharyngiomas.
    Reyes M; Taghvaei M; Yu S; Sathe A; Collopy S; Prashant GN; Evans JJ; Karsy M
    Front Biosci (Landmark Ed); 2022 Apr; 27(4):136. PubMed ID: 35468695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.